oxycodone and Sleep Wake Disorders

oxycodone has been researched along with Sleep Wake Disorders in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (33.33)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Binsfeld, H; Richarz, U; Sabatowski, R; Szczepanski, L; Waechter, S	1
Hanna, M; O'Brien, C; Wilson, MC	1
Sateia, MJ; Trzepacz, PT; Violette, EJ	1

Trials

2 trial(s) available for oxycodone and Sleep Wake Disorders

Article	Year
Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain. Pain practice : the official journal of World Institute of Pain, 2013, Volume: 13, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Pain; Drug Administration Schedule; Drug Delivery Systems; Emotions; Female; Follow-Up Studies; Humans; Hydromorphone; Male; Middle Aged; Oxycodone; Pain Measurement; Quality of Life; Sleep Wake Disorders; Time Factors; Treatment Outcome	2013
Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. European journal of pain (London, England), 2008, Volume: 12, Issue:6 Topics: Aged; Amines; Analgesics, Opioid; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Diabetic Neuropathies; Drug Synergism; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Oxycodone; Pain Measurement; Patient Satisfaction; Sleep Wake Disorders; Treatment Outcome	2008

Article

Year

Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.

Pain practice : the official journal of World Institute of Pain, 2013, Volume: 13, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Pain; Drug Administration Schedule; Drug Delivery Systems; Emotions; Female; Follow-Up Studies; Humans; Hydromorphone; Male; Middle Aged; Oxycodone; Pain Measurement; Quality of Life; Sleep Wake Disorders; Time Factors; Treatment Outcome

2013

Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.

European journal of pain (London, England), 2008, Volume: 12, Issue:6

Topics: Aged; Amines; Analgesics, Opioid; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Diabetic Neuropathies; Drug Synergism; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Oxycodone; Pain Measurement; Patient Satisfaction; Sleep Wake Disorders; Treatment Outcome

2008

Other Studies

1 other study(ies) available for oxycodone and Sleep Wake Disorders

Article	Year
Response to opioids in three patients with restless legs syndrome. The American journal of psychiatry, 1984, Volume: 141, Issue:8 Topics: Codeine; Female; Humans; Male; Methadone; Middle Aged; Myoclonus; Oxycodone; Receptors, Opioid; Restless Legs Syndrome; Sleep; Sleep Wake Disorders	1984